Kymera Investor Presentation Deck

KT-474/SAR444656: Hidradenitis Suppurativa (ZEN) Design: Double blind, placebo-controlled, 2-arm randomized trial; KT-474 oral tablet or placebo once-daily Enrollment: up to 99 subjects Duration: 16 weeks on therapy + 4 weeks of follow up Primary Outcome Measure: Percent change from baseline in total abscess and inflammatory nodule (AN) count Select Secondary Outcome Measures: ● ● ● ● ● Ongoing Phase 2 Trials in HS and AD Atopic Dermatitis (ADVANTA) Design: Double blind, placebo-controlled, 3-arm randomized trial; KT-474 dose 1 oral tablet, KT-474 dose 2 oral tablet or placebo once-daily Enrollment: up to 115 subjects Duration: 16 weeks on therapy + 4 weeks of follow up Primary Outcome Measure: Percent change from baseline in EASI Proportion of patients achieving HiSCR50, AN Count ≤2 Absolute change from baseline in IHS4 Proportion of patients with improvement in Hurley Stage, AN50 Change from baseline in reported daily worst pain HS-Skin Pain-NRS Proportion of participants achieving at least 30% reduction and at least 1 unit reduction in daily worst pain using HS-Skin Pain-NRS Primary Completion (Estimated): February 2025 Select Secondary Outcome Measures: Proportion of participants with vIGA-AD of 0 or 1 and a reduction from baseline of 22 points Proportion of participants achieving EASI-50 EASI-75 EASI-90 Proportion of participants with reduction of weekly average of daily PP-NRS by 24 points from baseline ● ● Percent change from baseline in weekly average of daily PP-NRS Absolute change from baseline in weekly average of daily PP-NRS Primary Completion (Estimated): January 2025 Additional information on the Phase 2 studies can be found at www.clinical trials.gov; identifier NCT06028230 (HS) and NCT06058156 (AD); Study Sponsor: Sanofi sanofi KYMERA HISCR50: Hidradenitis Suppurativa Clinical Response 50 | IHS4: International Hidradenitis Suppurativa Severity Score System | HS-Skin Pain-NRS: HS-Skin Pain-Numerical Rating Scale EASI: The Eczema Area and Severity Index; vIGA-AD: validated Investigational Global Assessment; PP-NRS: Peak Pruritus Numeric Rating Scale KYMERA ©2023 KYMERA THERAPEUTICS, INC. PAGE 20

View entire presentation